Utility of flow cytometric analysis of mast cells in the diagnosis and classification of adult mastocytosis

Leukemia Research

Volumn 25, Issue 7, 2001, Pages 563-570

  Escribano, Luis ^a   Díaz Agustín, Beatriz ^a   Bellas, Carmen ^a   Navalón, Raquel ^a   Nuñez, Rosa ^a   Sperr, Wolfgang R ^b   Schernthaner, Gerit Holger ^b   Valent, Peter ^b   Orfao, Alberto ^c  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

^b UNIVERSITY OF VIENNA   (Austria)

^c UNIVERSITY OF SALAMANCA   (Spain)

Author keywords

CD2; CD25; Diagnosis; Flow cytometry; Immunophenotype; Mast cells; Mastocytosis

Indexed keywords

ANTIGEN; CD2 ANTIGEN; INTERLEUKIN 2 RECEPTOR; TRYPTASE;

ADULT DISEASE; ANALYTIC METHOD; ANTIGEN EXPRESSION; ARTICLE; BONE MARROW DISEASE; CLINICAL FEATURE; DISEASE CLASSIFICATION; ENZYME BLOOD LEVEL; FLOW CYTOMETRY; HISTOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; MALIGNANT NEOPLASTIC DISEASE; MAST CELL; MASTOCYTOSIS; METHODOLOGY; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL;

ANTIGENS, CD2; BIOLOGICAL MARKERS; BONE MARROW; BONE MARROW CELLS; BONE MARROW EXAMINATION; CELL COUNT; ENZYME PRECURSORS; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MAST-CELL; MAST CELLS; MASTOCYTOSIS; PROTO-ONCOGENE PROTEINS C-KIT; RECEPTORS, INTERLEUKIN-2; SENSITIVITY AND SPECIFICITY; SERINE ENDOPEPTIDASES; STEM CELL FACTOR; TRYPTASES;

EID: 0034981905     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(01)00050-9     Document Type: Article

References (62)

1. Tissue mast cells in health and disease
2. Systemic mastocytosis
3. Systemic mastocytosis
4. Mast cell and mast cell neoplasia. A review
5. Systemic mastocytosis. Extracutaneous manifestations
6. Bone marrow findings in systemic mastocytosis
7. Systemic mast cell disease. Analysis of 58 cases and literature review
8. Systemic mastocytosis: Retrospective review of a decade's clinical experience at the Brigham and Women's Hospital
9. Clinical advances in mastocytosis: An interdisciplinary roundtable discussion
10. Biology, classification and treatment of human mastocytosis
11. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997
12. Mast cell disease
13. Lesions simulating lymphoma and miscellaneous tumor-like lesions in the bone marrow
14. Cutaneous mastocytosis in adults - Evaluation of 14 patients with respect to systemic disease manifestations
15. Urticaria pigmentosa: A clinical, hematopathologic, and serologic study of 30 adults
16. Systemic mast cell disease: A clinical and hematopathologic study of 26 cases
17. Morphologic properties of neoplastic mast cells: Delineation of stages of maturation and implication for cytological grading of mastocytosis
18. A new radioimmunoassay for human mast cell tryptase using monoclonal antibodies
19. Development of a new, more sensitive immunoassay for human tryptase: Use in systemic anaphylaxis
20. The alpha form of human tryptase is the predominant type present in blood at baseline in normal subjects and is elevated in those with systemic mastocytosis
21. Markers of mast cell degranulation
22. The potential clinical utility of serum α-protryptase levels
23. Diagnostic value of immunostaining for tryptase in patients with mastocytosis
24. Mast cell typing: Demonstration of a distinct hematopoietic cell type and evidence for immunophenotypic relationship to mononuclear phagocytes
25. The human cardiac mast cell: Localization, isolation, phenotype, and functional characterization
26. The phenotype of human eosinophils, basophils, and mast cells
27. Immunophenotypic characterization of human basophils and mast cells
28. Phenotypic characterization of human skin mast cells by combined staining with toluidine blue and CD antibodies
29. Expression of homing receptors and related molecules on human mast cells and basophils: A comparative analysis using multicolor flow cytometry and toluidine blue/immunofluorescence staining techniques
30. Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples. Identification and enumeration
31. Expression of lymphoid-associated antigens in mast cells: Report of a case of systemic mast cell disease
32. Sequential immunophenotypic analysis of mast cells in a case of systemic mast cell disease evolving to a mast cell leukemia
33. Indolent systemic mast cell disease in adults immunophenotypic characterization and its diagnostic implications
34. Immunophenotype of bone marrow mast cells in indolent systemic mast cell disease in adults
35. Flow cytometry immunophenotypic analysis of human mast cells
36. Immunophenotypic characterization of human bone marrow mast cells. A flow cytometric study of normal and pathological bone marrow samples
37. Further characterization of surface membrane structures expressed on human basophils and mast cells
38. Immunophenotyping and functional analysis of purified human uterine mast cells
39. Cell surface structures on human basophils and mast cells: Biochemical and functional characterization
40. Human bone marrow mast cells from indolent systemic mast cell disease constitutively express increased amounts of the CD63 protein on their surface
41. The CD69 early activation molecule is overexpressed in human bone marrow mast cells from adults with indolent systemic mast cell disease
42. Variable expression of activation-linked surface antigens on human mast cells in health and disease
43. Expression of bcl-2 by human bone marrow mast cells and its overexpression in mast cell leukemia
44. Flow cytometry is the most sensitive method for the diagnosis of bone marrow involvement in adult mastocytosis and allows a new classification of the adult indolent mastocytosis
45. Lymphoid cells and tissue mast cells of bone marrow lesions in systemic mastocytosis: A histological and immunohistological study
46. Comparative immunophenotypic analysis of human mast cells, blood basophils and monocytes
47. Human cell-adhesion molecule CD2 binds CD58 (LFA-3) with a very low affinity and an extremely fast dissociation rate but does not bind CD48 or CD59
48. Molecular interaction between CD58 and CD2 counter-receptors mediates the ability of monocytes to augment T cell activation by IL-12
49. Overlapping but nonidentical binding sites on CD2 for CD58 and a second ligand CD59
50. The biology of stem cell factor and its receptor C-kit
51. Adhesion of mouse mast cells to fibroblasts: Adverse effects of steel (Sl) mutation
52. Stem cell factor induces mast cell adhesion to fibronectin
53. Steel factor and c-kit regulate cell-matrix adhesion
54. Stem cell factor modulates avidity of alpha 4 beta 1 and alpha 5 beta 1 integrins expressed on hematopoietic cell lines
55. Cytokines increase human hemopoietic cell adhesiveness by activation of very late antigen (VLA)-4 and VLA-5 integrins
56. Elevated expression of the proto-oncogene c-kit in patients with mastocytosis
57. Mechanism of kit ligand, phorbol ester, and calcium-induced down-regulation of c-kit receptors in mast cells
58. Protein kinase C-dependent release of a functional whole extracellular domain of the mast cell growth factor (MGF) receptor by MGF-dependent human myeloid cells
59. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder
60. Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: Establishment of clonality in a human mast cell neoplasm
61. Systemic mastocytosis associated with acute myeloid leukaemia: Report of two cases and detection of c-kit mutation Asp-816 to Val
62. Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis